KR102488479B1 - 인플루엔자 바이러스 감염에 사용하기 위한 인돌 - Google Patents
인플루엔자 바이러스 감염에 사용하기 위한 인돌 Download PDFInfo
- Publication number
- KR102488479B1 KR102488479B1 KR1020177005979A KR20177005979A KR102488479B1 KR 102488479 B1 KR102488479 B1 KR 102488479B1 KR 1020177005979 A KR1020177005979 A KR 1020177005979A KR 20177005979 A KR20177005979 A KR 20177005979A KR 102488479 B1 KR102488479 B1 KR 102488479B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- amino
- added
- methyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPEP14180331.2 | 2014-08-08 | ||
| EP14180331 | 2014-08-08 | ||
| PCT/EP2015/068257 WO2016020526A1 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170039275A KR20170039275A (ko) | 2017-04-10 |
| KR102488479B1 true KR102488479B1 (ko) | 2023-01-12 |
Family
ID=51298610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177005979A Active KR102488479B1 (ko) | 2014-08-08 | 2015-08-07 | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10597390B2 (enExample) |
| EP (1) | EP3177609A1 (enExample) |
| JP (1) | JP6577570B2 (enExample) |
| KR (1) | KR102488479B1 (enExample) |
| CN (1) | CN106573920B (enExample) |
| AU (1) | AU2015298876B2 (enExample) |
| BR (1) | BR112017002370B1 (enExample) |
| CA (1) | CA2954751C (enExample) |
| CL (1) | CL2017000309A1 (enExample) |
| EA (1) | EA201790266A1 (enExample) |
| IL (1) | IL250408B (enExample) |
| MA (1) | MA40547A (enExample) |
| MX (1) | MX381488B (enExample) |
| PH (1) | PH12017500207B1 (enExample) |
| SG (1) | SG11201700956VA (enExample) |
| UA (1) | UA124609C2 (enExample) |
| WO (1) | WO2016020526A1 (enExample) |
| ZA (1) | ZA201700952B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| JP6577570B2 (ja) | 2014-08-08 | 2019-09-18 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | インフルエンザウイルス感染に使用するためのインドール類 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| EP3362451B1 (en) | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| EA201891576A1 (ru) * | 2016-01-07 | 2018-11-30 | Янссен Сайенсиз Айрлэнд Юси | Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2018033082A1 (en) * | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) * | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| CN110623958B (zh) | 2016-09-05 | 2022-05-17 | 广东众生睿创生物科技有限公司 | 抗流感病毒嘧啶衍生物 |
| JP7034162B2 (ja) | 2016-12-15 | 2022-03-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | インフルエンザウイルス複製の阻害剤及びその使用 |
| US11542233B2 (en) * | 2016-12-23 | 2023-01-03 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| CN108727369B (zh) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| KR102484804B1 (ko) * | 2018-03-05 | 2023-01-04 | 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 | 이미다졸계 화합물의 결정 형태, 염 형태 및 그의 제조 방법 |
| US12252487B2 (en) | 2019-07-22 | 2025-03-18 | Guangdong Raynovent Biotech Co., Ltd. | Dominant salt forms of pyrimidine derivatives, and crystal forms thereof |
| CN113045475A (zh) * | 2019-12-27 | 2021-06-29 | 上海泓博智源医药股份有限公司 | 一种5-溴-7-甲基吲哚的制备方法 |
| WO2022020342A1 (en) * | 2020-07-20 | 2022-01-27 | Nido Biosciences, Inc. | Indole compounds as androgen receptor modulators |
| US20240010643A1 (en) * | 2020-09-18 | 2024-01-11 | Sunshine Lake Pharma Co., Ltd. | Preparation method of substituted pyrimidine piperazine compounds |
| IL320191A (en) * | 2022-10-12 | 2025-06-01 | Maze Therapeutics Inc | Solute carrier family 6A member 19 inhibitors (SLC6A19) and methods of using them |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012083122A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| WO2013019828A1 (en) | 2011-08-01 | 2013-02-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2560454C (en) | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| CN103492381A (zh) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| EP2763990B1 (en) | 2011-09-01 | 2017-02-22 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| HRP20191525T1 (hr) | 2013-11-13 | 2019-11-29 | Vertex Pharma | Inhibitori replikacije virusa influence |
| AR101401A1 (es) | 2014-08-08 | 2016-12-14 | Bayer Cropscience Ag | Derivados de bipirazol, sustituidos con halógeno |
| JP6577570B2 (ja) | 2014-08-08 | 2019-09-18 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | インフルエンザウイルス感染に使用するためのインドール類 |
| AR101448A1 (es) | 2014-08-08 | 2016-12-21 | Bayer Cropscience Ag | Compuestos sustituidos por halógeno |
| CN104592038A (zh) | 2015-01-12 | 2015-05-06 | 烟台万润精细化工股份有限公司 | 一种5,5-二甲基-1,3-环己二胺的制备方法 |
-
2015
- 2015-08-07 JP JP2017506964A patent/JP6577570B2/ja not_active Expired - Fee Related
- 2015-08-07 UA UAA201702154A patent/UA124609C2/uk unknown
- 2015-08-07 BR BR112017002370-9A patent/BR112017002370B1/pt not_active IP Right Cessation
- 2015-08-07 MX MX2017001752A patent/MX381488B/es unknown
- 2015-08-07 AU AU2015298876A patent/AU2015298876B2/en not_active Ceased
- 2015-08-07 EP EP15750365.7A patent/EP3177609A1/en not_active Withdrawn
- 2015-08-07 KR KR1020177005979A patent/KR102488479B1/ko active Active
- 2015-08-07 MA MA040547A patent/MA40547A/fr unknown
- 2015-08-07 WO PCT/EP2015/068257 patent/WO2016020526A1/en not_active Ceased
- 2015-08-07 CA CA2954751A patent/CA2954751C/en active Active
- 2015-08-07 EA EA201790266A patent/EA201790266A1/ru unknown
- 2015-08-07 US US15/501,730 patent/US10597390B2/en not_active Expired - Fee Related
- 2015-08-07 SG SG11201700956VA patent/SG11201700956VA/en unknown
- 2015-08-07 CN CN201580042406.9A patent/CN106573920B/zh not_active Expired - Fee Related
-
2017
- 2017-02-02 PH PH12017500207A patent/PH12017500207B1/en unknown
- 2017-02-02 IL IL250408A patent/IL250408B/en active IP Right Grant
- 2017-02-07 ZA ZA2017/00952A patent/ZA201700952B/en unknown
- 2017-02-07 CL CL2017000309A patent/CL2017000309A1/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012032065A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012083122A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| WO2013019828A1 (en) | 2011-08-01 | 2013-02-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170226102A1 (en) | 2017-08-10 |
| IL250408B (en) | 2020-08-31 |
| UA124609C2 (uk) | 2021-10-20 |
| EP3177609A1 (en) | 2017-06-14 |
| PH12017500207A1 (en) | 2017-07-10 |
| MX381488B (es) | 2025-03-12 |
| JP6577570B2 (ja) | 2019-09-18 |
| BR112017002370A2 (pt) | 2017-12-05 |
| ZA201700952B (en) | 2018-12-19 |
| CN106573920B (zh) | 2020-11-10 |
| AU2015298876B2 (en) | 2020-02-13 |
| CL2017000309A1 (es) | 2017-08-18 |
| SG11201700956VA (en) | 2017-03-30 |
| CN106573920A (zh) | 2017-04-19 |
| EA201790266A1 (ru) | 2017-06-30 |
| IL250408A0 (en) | 2017-03-30 |
| CA2954751C (en) | 2023-01-17 |
| BR112017002370B1 (pt) | 2022-11-22 |
| US10597390B2 (en) | 2020-03-24 |
| AU2015298876A1 (en) | 2017-02-02 |
| MX2017001752A (es) | 2018-02-08 |
| JP2017523225A (ja) | 2017-08-17 |
| CA2954751A1 (en) | 2016-02-11 |
| PH12017500207B1 (en) | 2017-07-10 |
| WO2016020526A1 (en) | 2016-02-11 |
| KR20170039275A (ko) | 2017-04-10 |
| MA40547A (fr) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102488479B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 | |
| KR102531340B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 피롤로피리미딘 | |
| US11117887B2 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
| ES2882671T3 (es) | Indoles heterocíclicos para su uso en infecciones por el virus de la gripe | |
| US9771361B2 (en) | Inhibitors of influenza viruses replication | |
| JP7001601B2 (ja) | インフルエンザウイルス感染に使用するための官能化ペンタン酸 | |
| KR20200116099A (ko) | Rsv에 대한 활성을 갖는 시클로알킬 치환 피라졸로피리미딘 | |
| HK1236532B (zh) | 用於在流感病毒感染中使用的吲哚 | |
| HK1236532A1 (en) | Indoles for use in influenza virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170302 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200717 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220706 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20221007 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230110 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230110 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |